Auditory P300 as a predictor of short-term prognosis in subjects at clinical high risk for psychosis
Introduction
Early psychosis detection and intervention have been matters of grave concern for many years. ‘Clinical high risk (CHR)’ or ‘ultra-high risk’ criteria were established to identify subjects at imminent risk of psychotic disorder (Miller et al., 2003, Yung et al., 2004). Although longitudinal studies demonstrated the predictive value of these criteria, the initially reported high transition rates have been decreasing in subjects at CHR for psychosis (Miller et al., 2002, Yung et al., 2007, Simon et al., 2011). Recently, an increasing portion of CHR subjects who do not convert to psychosis (i.e., non-converters) has resulted in more attention being paid to the prognosis of this group (Ziermans et al., 2011, Schlosser et al., 2012).
CHR non-converters are a heterogeneous group in terms of their prognosis, and consist of individuals who are in remission, who are neither remitted nor converted, and who later will convert to psychosis (Velthorst et al., 2011, de Wit et al., 2014). Therefore, early detection of putative remitters in CHR non-converters may be helpful in reducing problems with false positives, such as application of inappropriate treatment and social stigmatization. Furthermore, considering that some CHR non-converters are non-remitters with sustained prodromal symptoms and even symptomatic remitters are remained at poor functional status (Addington et al., 2011, Lee et al., 2014a), factors predictive of the clinical course in CHR non-converters would provide useful guidelines for decision making regarding appropriate interventions. Despite its clinical importance, few studies of prediction of the prognosis of CHR non-converters have been conducted (Lee et al., 2014b, Lin et al., 2015).
In addition, there are studies suggesting that clinical manifestations other than positive prodromal symptoms may be important in subjects at CHR for psychosis (Lencz et al., 2004, Addington et al., 2011, Fusar-Poli et al., 2014). Fusar-Poli et al. reported that Axis I comorbidity of depressive and anxiety disorders is high in CHR subjects, and is associated with negative symptoms and functional impairment (Fusar-Poli et al., 2014). According to Lencz et al., negative symptoms were related with later conversion to psychotic disorder in CHR subjects (Lencz et al., 2004). Addington et al. also noted that attenuated positive symptoms may predict a more severe condition in some cases, but not in all CHR subjects, and thus better predictors are needed (Addington et al., 2011). Therefore, future studies aimed at identifying factors associated with the clinical prognosis of CHR subjects—other than positive prodromal symptoms such as negative symptoms, general symptoms or neurophysiological variables—would be of great interest.
P300 is a late cognitive component of event-related potentials (ERPs), which is thought to reflect a working memory update of change and attention (Nieman et al., 2002). A large number of studies found that P300 amplitude is reduced in patients with schizophrenia, as well as in their biological relatives (Winterer et al., 2003, Bramon et al., 2004). These findings suggest that P300 may be a potential trait marker for psychosis. On the other hand, evidence supporting the notion that P300 could be used as a state marker for symptom severity also exists (Mathalon et al., 2000, Higashima et al., 2003). Therefore, P300 can be simultaneously a trait marker for psychosis and a state marker for symptom change. Thus, P300 can be also useful in predicting the prognosis, in terms of both psychotic transition and symptom change, of subjects at CHR for psychosis.
In CHR subjects, P300 amplitude was found to be reduced compared with that of healthy controls (van der Stelt et al., 2005, Bramon et al., 2008, Ozgurdal et al., 2008). P300 impairment was more severe in CHR converters than that in CHR non-converters, and reduced parietal P300 predicted later development of a psychotic episode (van Tricht et al., 2010, Nieman et al., 2013). However, little is known regarding P300 as a prognosis predictor in subjects at CHR, other than psychotic transition. Regarding recent concern about CHR non-converters and the potential role of P300 as a marker for symptom change, it would be interesting to attempt to predict symptomatic improvement in CHR non-converters using P300.
In this study, we aimed to investigate whether P300 predicts the outcome specifically for CHR subjects who did not convert to psychosis during the 2-year follow-up period. We hypothesized that individuals who remitted from their initial prodromal state would display greater baseline P300 amplitude than those who did not remit. We also hypothesized that greater baseline P300 amplitude would predict more symptomatic and functional improvement in CHR non-converters within 2 years.
Section snippets
Participants
141 CHR subjects were recruited from November 2004 to January 2014 via a prospective, longitudinal CHR study in the Seoul Youth Clinic (Kim et al., 2012). CHR status was assessed using the Structural Interview of Prodromal Symptoms (SIPS) criteria (Miller et al., 2002, Jung et al., 2010). Past and current psychiatric disorders were determined using the Structural Clinical Interview for DSM-IV Axis I (SCID-I). Exclusion criteria included a lifetime diagnosis of psychotic illness, history of
Subject characteristics
At the point of baseline P300 and clinical assessment, all CHR subjects were antipsychotic-naïve; 29 subjects were drug-naïve, 8 subjects were taking antidepressants, 1 subject was taking a mood stabilizer, and 10 subjects were taking benzodiazepines. Among the 45 CHR non-converters who had baseline ERP data and at least one follow-up assessment over 2 years, 19 subjects remitted from CHR status and 26 subjects remained in the prodromal status for psychosis. There was no difference in
Discussion
To our knowledge, this is the first study to investigate short-term prognosis in CHR non-converters using P300. Inconsistent with our initial hypothesis, there was no difference in baseline P300 amplitude between the CHR-R and CHR-NR groups, which were classified according to remission criteria based on improvement in positive prodromal symptoms and general functional status. Nevertheless, P300 peak amplitude significantly predicted later improvement in negative and general symptoms during the
Role of funding source
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (Grant no. 2013R1A2A1A03071089).
Contributors
Minah Kim, Tae Young Lee, Sung Nyun Kim and Jun Soo Kwon designed the study. Minah Kim, Tae Young Lee, and Sung Nyun Kim contributed to the participants' enrollment and clinical assessment. Suji Lee collected event-related potentials (ERPs) data. Minah Kim performed the statistical analysis and wrote the manuscript. Tae Young Lee and Sung Nyun Kim supported the statistical analysis and interpretation of the data. Jun Soo Kwon managed and supervised the whole procedure of this study. All authors
Conflict of interest
All authors have no conflict of interest to declare.
Acknowledgments
The authors have no acknowledgements to make.
References (42)
- et al.
Meta-analysis of the P300 and P50 waveforms in schizophrenia
Schizophr. Res.
(2004) - et al.
Abnormal P300 in people with high risk of developing psychosis
NeuroImage
(2008) - et al.
Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state
Eur. Neuropsychopharmacol.
(2014) - et al.
Auditory P300 amplitude as a state marker for positive symptoms in schizophrenia: cross-sectional and retrospective longitudinal studies
Schizophr. Res.
(2003) - et al.
Pharmacotherapy and clinical characteristics of ultra-high-risk for psychosis according to conversion status: a naturalistic observational study
Early Interv. Psychiatry
(2012) - et al.
Impaired mismatch negativity is associated with current functional status rather than genetic vulnerability to schizophrenia
Psychiatry Res.
(2014) - et al.
Symptomatic and functional remission of subjects at clinical high risk for psychosis: a 2-year naturalistic observational study
Schizophr. Res.
(2014) - et al.
Neurocognitive function as a possible marker for remission from clinical high risk for psychosis
Schizophr. Res.
(2014) - et al.
Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia
Schizophr. Res.
(2004) - et al.
Positive and negative symptom profile schizophrenia and abnormalities in the P300 component of the event-related potential: a longitudinal controlled study
Psychiatry Res.
(2004)
Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study
Biol. Psychiatry
Clinical and neuropsychological correlates of the P300 in schizophrenia
Schizophr. Res.
Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia
Schizophr. Res.
Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data
Schizophr. Res.
Ultra high-risk state for psychosis and non-transition: a systematic review
Schizophr. Res.
Auditory event-related potentials in 50 melancholic patients: increased N100, N200 and P300 latencies and diminished P300 amplitude
J. Affect. Disord.
Auditory P300 in high-risk, recent-onset and chronic schizophrenia
Schizophr. Res.
Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode
Biol. Psychiatry
Current status specifiers for patients at clinical high risk for psychosis
Schizophr. Res.
Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features
Schizophr. Res.
Transition and remission in adolescents at ultra-high risk for psychosis
Schizophr. Res.
Cited by (24)
P300 in schizophrenia: Then and now
2024, Biological PsychologyForecasting Remission From the Psychosis Risk Syndrome With Mismatch Negativity and P300: Potentials and Pitfalls
2021, Biological Psychiatry: Cognitive Neuroscience and NeuroimagingCitation Excerpt :To date, most studies attempting to identify predictors of CHR remission have tended to treat remission as a binary clinical outcome, comparing remitters with nonremitters, and have included among the nonremitters those CHR individuals who progressed to full psychosis. Indeed, both MMN studies described above (55,57) included converters in the nonremitter group, while the P300 studies either excluded converters from their analysis (83) or considered converters separately from nonremitters with a persistent CHR syndrome (25,81). The dichotomization of remission outcomes creates the potential for the predictors of remission to be confounded by the prediction of conversion effects.
Neuroimaging Markers of Resiliency in Youth at Clinical High Risk for Psychosis: A Qualitative Review
2021, Biological Psychiatry: Cognitive Neuroscience and NeuroimagingP300 as an index of transition to psychosis and of remission: Data from a clinical high risk for psychosis study and review of literature
2020, Schizophrenia ResearchCitation Excerpt :Some CHR studies suggested that subtle reduction of P300 oddball amplitude precede the onset of psychosis (van der Stelt et al., 2005; Bramon et al., 2008; Ozgurdal et al., 2008; van Tricht et al., 2010; Fusar-Poli et al., 2011b, 2011a). van Tricht et al. (2011) first reported lower P300 amplitude in CHR converters than non-converters, whereas Kim et al. (2015) found no P300 group differences between CHR remitters and non-remitters. Nieman et al. (2014) improved an individual risk estimation developed in this study after adding P300 oddball amplitude and premorbid adjustment to the model.
P300 amplitude attenuation in high risk and early onset psychosis youth
2019, Schizophrenia ResearchCitation Excerpt :Such research is critical given the benefits of early intervention for preventing conversion to psychosis in CHR and worsening of symptoms in PS (Ising et al., 2017). Numerous reports demonstrate P300 differences between adult high risk and schizophrenia patients versus healthy controls at midline scalp electrode locations Fz, Cz, and Pz (Bramon et al., 2004; Frommann et al., 2008; Jeon and Polich, 2003; Kim et al., 2015). The subcomponents of the P300, the “novelty detection” P3a and the “target detection” P3b, have both been highlighted in schizophrenia research: Studies have shown P3a amplitude reduction in chronic schizophrenia patients (Mathalon et al., 2010) and in clinical high risk as well as first episode adults (del Re et al., 2015; Jahshan et al., 2012; Mondragón-Maya et al., 2013).